Abstract:Graphical Preclinical studies support the role of BDNF as a biomarker in Neuropathic Pain. This study identified several methodological considerations that need to be accounted for when measuring BDNF peripherally. Additional longitudinal investigations are needed to develop standardized guidelines to measure serum BDNF and to clearly determine its role in the diagnosis and treatment of neuropathic pain. Introduction The primary objective of this paper is to (1) provide a summary of human studies that have used brain derived neurotrophic factor (BDNF) as a biomarker, (2) review animal studies that help to elucidate the mechanistic involvement of BDNF in the development and maintenance of neuropathic pain (NP), and (3) provide a critique of the existing measurement techniques to highlight the limitations of the methods utilized to quantify BDNF in different biofluids in the blood (i.e., serum and plasma) with the intention of presenting a case for the most reliable and valid technique. Lastly, this review also explores potential moderators that can influence the measurement of BDNF and provides recommendations to standardize its quantification to reduce the inconsistencies across studies. Methods In this manuscript we examined the literature on BDNF, focusing on its role as a biomarker, its mechanism of action in NP, and critically analyzed its measurement in serum and plasma to identify factors that contribute to the discrepancy in results between plasma and serum BDNF values. Results A large heterogenous literature was reviewed that detailed BDNF's utility as a potential biomarker in healthy volunteers, patients with chronic pain, and patients with neuropsychiatric disorders but demonstrated inconsistent findings. The literature provides insight into the mechanism of action of BDNF at different levels of the central nervous system using animal studies. We identified multiple factors that influence the measurement of BDNF in serum and plasma and based on current evidence, we recommend assessing serum BDNF levels to quantify peripheral BDNF as they are more stable and sensitive to changes than plasma BDNF. Conclusion Although mechanistic studies clearly explain the role of BDNF, results from human studies are inconsistent. More studies are needed to evaluate the methodological challenges in using serum BDNF as a biomarker in NP.

Serum brain-derived neurotrophic factor levels in patients with diabetic neuropathic pain

Diagnostic Significance of Serum Levels of Nerve Growth Factor and Brain Derived Neurotrophic Factor in Diabetic Peripheral Neuropathy.

Levels of Brain Natriuretic Peptide Are Associated with Peripheral Arterial Disease in Subjects with Type-2 Diabetes Mellitus

Systematic Administration of B Vitamins Alleviates Diabetic Pain and Inhibits Associated Expression of P2X3 and TRPV1 in Dorsal Root Ganglion Neurons and Proinflammatory Cytokines in Spinal Cord in Rats

Physiological Serum Total Bilirubin Concentrations Were Inversely Associated with Diabetic Peripheral Neuropathy in Chinese Patients with Type 2 Diabetes: a Cross-Sectional Study

Relationship between level of serum vitamin D and peripheral neuropathy in type 2 diabetes mellitus patients

Serum Levels Ofneurotrophic Factors in Diabetic Retinopathy Patients

BDNF as a biomarker for neuropathic pain: Consideration of mechanisms of action and associated measurement challenges

Decreased amino acids in the brain might contribute to the progression of diabetic neuropathic pain

Branched-Chain Amino Acids Deficiency Promotes Diabetic Neuropathic Pain Through Upregulating LAT1 and Inhibiting Kv1.2 Channel

Decreased Physiological Serum Total Bile Acid Concentrations in Patients with Type 2 Diabetic Peripheral Neuropathy.

Serum Spexin Level Is Negatively Associated With Peripheral Neuropathy and Sensory Pain in Type 2 Diabetes

Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy

Serum Adiponectin Levels Are Positively Associated With Diabetic Peripheral Neuropathy in Chinese Patients With Type 2 Diabetes

Association of Diabetic Peripheral Neuropathy with Vitamin D Levels Depends on Vitamin D Status

VEGF-B is involved in diabetic peripheral neuropathy in patients with type 2 diabetes

The limited role of serum neurofilament light chain in predicting pain severity of patients with diabetic polyneuropathy

Eleven neurology-related proteins measured in serum are positively correlated to the severity of diabetic neuropathy

Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy

Serum brain-derived neurotrophic factor levels in type 2 diabetes mellitus patients and its association with cognitive impairment: A meta-analysis

Sensorimotor and Pain‐related Alterations of the Gray Matter and White Matter in Type 2 Diabetic Patients with Peripheral Neuropathy